Quantcast
Home > Quotes > ECOR

electroCore, Inc. Common Stock (ECOR) Quote & Summary Data

ECOR 
$6.605
*  
0.165
2.44%
Get ECOR Alerts
*Delayed - data as of Nov. 19, 2018 12:23 ET  -  Find a broker to begin trading ECOR now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    ECOR Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 6.60 / $ 6.79
1 Year Target
23
Today's High / Low
$ 6.77 / $ 6.41
Share Volume
23,030
50 Day Avg. Daily Volume
79,192
Previous Close
$ 6.77
52 Week High / Low
$ 20.25 / $ 6.24
Market Cap
194,517,475
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0.81

Intraday Chart

Shares Traded

Share Volume:
23,030
50 Day Avg. Daily Volume:
79,192

Trading Range

The current last sale of $6.605 is 5.85% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 6.77 $ 20.25
 Low: $ 6.41 $ 6.24

Company Description (as filed with the SEC)

We are a commercial-stage bioelectronic medicine company with a platform non-invasive vagus nerve stimulation therapy initially focused on neurology and rheumatology. Our therapy, gammaCore, has pharmacologic effects on the peripheral and central nervous systems, which modulate neurotransmitters and immune function. gammaCore is FDA-cleared for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Based on our clinical data, we are pursuing label expansions for the prevention of migraine, migraine in adolescents and post-traumatic headache, and we are also engaging in clinical development for potential new labeling claims in rheumatology, including Sjögren's syndrome and rheumatoid arthritis. gammaCore is the first FDA-cleared, prescription-only vagus nerve stimulation, or VNS, therapy administered in discrete doses using a proprietary, simple-to-use handheld delivery system.  ... More ...  


Risk Grade

Where does ECOR fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.77
Open Date:
Nov. 19, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x